Skip to content
RNAWiki

Tazarotene

  • Prescription medicine
  • Prescription only
  • Identity checked
  • Sources last checked 2026-09-04

This page shows what was measured, who it was measured in, and what that does not settle.

What Tazarotene does in the body

1% is a retinoid indicated for the topical treatment of plaque psoriasis of up to 20% body surface area involvement.

From the FDA-approved label: Tazarotene is a retinoid prodrug that is converted to its active form, the cognate carboxylic acid of tazarotene, by rapid deesterification in animals and man. Tazarotenic acid binds to all 3 members of the retinoic acid receptor (RAR) family: RARα, RARβ, and RARγ but shows relative selectivity for RARβ and RARγ and may modify gene expression. The clinical significance of these findings is unknown. The mechanism of tazarotene action in acne vulgaris is not defined. However, the basis of tazarotene's therapeutic effect in acne may be due to its anti-hyperproliferative, normalizing-of-differentiation and anti-inflammatory effects.

Why people take it. • Tazarotene gel, 0.05% and 0.1% is a retinoid indicated for the topical treatment of plaque psoriasis of up to 20% body surface area involvement.

What happened in people

RNAWiki has not yet published a reviewed conclusion for this use.

A fixed RNAWiki sentence

Where this came from

Wording RNAWiki always uses, not a finding about this substance.

No reviewed claim names a result for any goal on this record.

No source is stored against this line.

The limit that matters most

Not recorded.

Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.

What the registries record it as

  • The substance registry classes this as chemical.

    FDA substance registry · 81BDR9Y8PS · read 2026-08-29

  • Its recorded molecular formula is C21H21NO2S, weighing 351.46.

    US prescribing information · aa6fff2f-01c7-4669-be67-07cec82c768a · read 2026-08-30

Where each sentence above came from

The use the label states, quoted from it. No plain-language version of this sentence has been written.

The use the label states, quoted from it. It is written for a clinician, not for a reader without medical training.

No statement of the main limit is recorded.

The four opening statements run to 155 words.

Words this page uses

Four words worth knowing first

Chosen from what this page shows, with each one explained before the word it depends on.

Biomarker

A biomarker is a number from a test that stands in for something about health.

A picture of it, and where the picture fails

A biomarker is like a fuel gauge.

Where that stops being true. A gauge is wired to the tank. Many biomarkers are only loosely tied to health.

What people get wrong. A better number is read as a better life. Several medicines improved a number and helped nobody.

A measurable indicator used as a substitute for a clinical outcome of interest.

Placebo

A placebo is a dummy treatment given so the real one can be compared with it.

A picture of it, and where the picture fails

A placebo is like a blank control in an experiment.

Where that stops being true. A blank does nothing. People given a placebo often do get better.

What people get wrong. A placebo effect is read as imaginary. The improvement is measured and real.

An inactive intervention matched in appearance to the test intervention, used to control for non-specific effects.

Comparator

A comparator is whatever the treatment was measured against.

A picture of it, and where the picture fails

It is like the other runner in a race.

Where that stops being true. A race has one winner. A study can show both arms improved.

What people get wrong. Results are read without asking what the other group got. Beating nothing is not beating a treatment.

The control condition against which the experimental intervention is assessed.

What happened in peopleRead from sources, not yet reviewed

What happened in people

Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.

Evaluation of equivalence of the test product to the reference product

The study did not show it

Who was studied
NCT02160678
How many people
1741
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Topical

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Change in Inflammatory Lesion Counts

The study did not show it

Who was studied
NCT02886715
How many people
1110
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Topical

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Change in inflammatory lesion counts

The study did not show it

Who was studied
NCT02411955
How many people
1077
Study design
Phase 1
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Topical

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Percent Change in the Inflammatory (Papules and Pustules) Lesion Counts

The study did not show it

Who was studied
NCT02267746
How many people
893
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Topical

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

primary efficacy endpoint

The study did not show it

Who was studied
NCT02160665
How many people
866
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Topical

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Treatment Success Assessed by IGA

The study did not show it

Who was studied
NCT02886702
How many people
855
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Topical

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.

What is missing or unclearRead from sources, not yet reviewed

Were people like you studied?

RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.

Who was studied

People similar to this profile were included.

  • Tazarotene cream, 0.1% is indicated as an adjunctive agent for use in the mitigation (palliation) of facial fine wrinkling, facial mottled hyper-and hypopigmentation, and benign facial lentigines in patients who use comprehensive skin care and sunlight avoidance programs.

Who is missing from the studies

  • Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What the label states about particular groups

  • On pediatric, the label states: “The safety and efficacy of tazarotene gel have not been established in pediatric patients with psoriasis or acne under the age of 12 years.”

    US prescribing information · aa6fff2f-01c7-4669-be67-07cec82c768a · read 2026-08-30

  • On older people, the label states: “Of the total number of subjects in clinical trials of tazarotene gel for plaque psoriasis, 163 were over the age of 65.”

    US prescribing information · aa6fff2f-01c7-4669-be67-07cec82c768a · read 2026-08-30

  • On people who are pregnant, the label states: “Safety in pregnant females has not been established.”

    US prescribing information · aa6fff2f-01c7-4669-be67-07cec82c768a · read 2026-08-30

  • On people who are breastfeeding, the label states: “Risk Summary There is no information regarding the presence of tazarotene in human milk, the effects on the breastfed infant, or the effects on milk production.”

    US prescribing information · aa6fff2f-01c7-4669-be67-07cec82c768a · read 2026-08-30

Where the result stopped carrying

  • This is a scope explorer, not a diagnosis engine.
  • It shows who was studied so you can see whether people similar to you were included.

RNAWiki cannot tell whether a study fits you. It can show who was in it.

What it would be like to takeRead from sources, not yet reviewed

Why it might seem to do nothing

A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.

It was studied in different people

The people in the studies were not much like the reader.

On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

The evidence may simply be wrong

Small early studies often do not hold up.

On this record: RNAWiki has not yet published a reviewed conclusion for this use.

Other reasons RNAWiki checked and found nothing for (11)
It was studied for a different goal
The studies measured something else entirely. Nothing in this record points to this reason.
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.

None of these is a reason to take more. Taking more is not a step this page ever suggests.

What it would be like to takeRead from sources, not yet reviewed

What taking it involves

The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.

How it is supplied

Prescription only

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

Read from the recorded approval status.

No source is stored against this line.

Form and route

Topical

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

The form and route recorded on this substance.

No source is stored against this line.

Who oversees it

Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

Suppression classes recorded: S3.

No source is stored against this line.

What is in the pack

Sold as cream, gel, lotion, aerosol, foam, given by the topical, cutaneous route.

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

Recorded notes on how this is sold and what that means for what is in the pack.

No source is stored against this line.

Where it is registered

Regulatory records are listed in the technical disclosure at the foot of this page.

Counted from records

Where this came from

A count of rows RNAWiki holds. It describes our records, not your body.

Register entries are stored per jurisdiction and shown with their dates.

No source is stored against this line.

Why people stop

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

No record of why people stopped taking it is stored for this substance.

No source is stored against this line.

What it would be like to takeNothing found in the sources checked

What can go wrong

Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.

Nothing found in the sources checked

No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.

The sources listed were searched and held nothing. That is not the same as nothing existing.

Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.

Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What is missing or unclearRead from sources, not yet reviewed

Does the exact form matter?

Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.

The form that was studied

Topical

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

The form used in the studies cited on this page.

No source is stored against this line.

What is sold

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

Nothing further is recorded about which forms are sold.

No source is stored against this line.

What is recorded as being sold

  • 32 products list this as an active ingredient in the United States drug directory. 31 of them contain it and nothing else.

    FDA National Drug Code directory · 87143-200 · read 2026-08-29

  • They are sold as aerosol, foam, cream, gel, lotion and powder, taken cutaneous and topical.

    FDA National Drug Code directory · 87143-200 · read 2026-08-29

  • The regulator's established pharmacologic class for it is retinoid [epc] and retinoids [cs].

    FDA National Drug Code directory · 87143-200 · read 2026-08-29

  • 18 published labels name it as an active ingredient. 17 of them describe this substance alone, which is where its own label text on this page comes from.

    US prescribing information · aa6fff2f-01c7-4669-be67-07cec82c768a · read 2026-08-29

  • Those labels are classed as human prescription drug.

    US prescribing information · aa6fff2f-01c7-4669-be67-07cec82c768a · read 2026-08-29

  • TAZAROTENE is topical at 3 DOSAGE FORMS AND STRENGTHS Gel, 0.05% and 0.1%, in 30 g and 100 g tubes., recorded as fda label in effect 2024-05-29 in the United States.

    US prescribing information · aa6fff2f-01c7-4669-be67-07cec82c768a · read 2026-08-30

  • Recorded price in US: 1.82453–8.00464 USD per one gram, across 18 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..

    Recorded source · 2026-08-26 · read 2026-08-28

Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.

What it would be like to takeRead from sources, not yet reviewed

What you could measure

This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.

Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.

Questions worth asking

  • Which of the trials of Tazarotene studied people like me?
  • What was measured, and for how long?
  • Was the result a laboratory value or a health outcome?
  • What would we watch for, and when would we stop?

Tracking can show whether something changed for you. It cannot show what caused it.

RNAWiki records evidence. It does not say whether this substance is right for you.

What is missing or unclearRead from sources, not yet reviewed

What nobody knows yet

Open questions, each with why it is open and what would close it.

Missing populations

Which groups were under-represented in the studies has not been recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing long-term data

No completed tested study window is recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

No reviewed conclusion

RNAWiki has not yet published a reviewed conclusion for this use.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing interaction studies

No interaction was found in the registers checked. Not finding one is not the same as showing there is none.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Formulation uncertainty

Several salts, forms or products of Tazarotene are recorded. Results from one form may not transfer to another.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Mechanism not reviewed

No reviewed mechanism story exists for this substance.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

What happened in peopleRead from sources, not yet reviewed

Check any of this yourself

Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.

How many documents were read

  • 17 documents were read for this substance.

    RNAWiki source record

  • 14 of them state the same halfLife, and they agree.

    RNAWiki source record

  • 2 of them state the same tMax, and they agree.

    RNAWiki source record

  • 17 of them state the same proteinBinding, and they agree.

    RNAWiki source record

Where else this substance is registered

FDA substance identifier (UNII)
81BDR9Y8PS
RxNorm concept
313201

Checks this page had to pass

  • Passed

    Identity resolved

    no open identity hold

  • Passed

    No unresolved merge across substance families

    no quarantine open

  • Passed

    Every public sentence names a source

    The opening statement carries the origin: Quoted from a stored source.

  • Not passed

    Trial roles classified for highlighted evidence

    No registered study is classified as testing this substance.

  • Passed

    No internal keys in reader text

    enforced by the copy-contract test over the rendered page

  • Passed

    Safety mode resolved

    Suppression classes recorded: S3.

  • Passed

    Canonical metadata present

    slug and display name present

What is missing or unclearRead from sources, not yet reviewed

How this medicine reached us

Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.

What the approval register records

  • 16 approved applications cover products containing this substance. The earliest was NDA020600, approved 19970613 to ALMIRALL.

    Drugs@FDA application register · NDA020600 · read 2026-08-29

  • Marketing status on the register: discontinued and prescription.

    Drugs@FDA application register · NDA020600 · read 2026-08-29

  • The earliest marketing start date recorded for a listed product is 19960401.

    FDA National Drug Code directory · 87143-200 · read 2026-08-29

What is missing or unclearRead from sources, not yet reviewed

What to learn next

Ordered by what would most change how you read this page, starting with what is easiest to misunderstand.

This order is fixed in code and does not count clicks or time on the page.

What is not here

9 questions this page could not answer

These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.

  • What was measured, goal by goal — found nothing in the sources checked.
  • How close this is to real life — found nothing in the sources checked.
  • The path through the body — found nothing in the sources checked.
  • Felt, measured, or meaningful — found nothing in the sources checked.
  • How long anything takes — found nothing in the sources checked.
  • What it may clash with — found nothing in the sources checked.
  • Other ways to the same goal — found nothing in the sources checked.
  • Claims that go past the evidence — found nothing in the sources checked.
  • What changed on this page — found nothing in the sources checked.

The record as stored

The full record, for auditing

Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.

Recorded evidence blocks (9)

On the Tazarotene label: indicated for what?

"Trilitas™ gel, 0.1% is a retinoid indicated for the topical treatment of plaque psoriasis of up to 20% body surface area involvement. ( 1.1 ) Trilitas™ gel, 0.1% is indicated for the topical treatment of mild to moderate facial acne vulgaris.": indications and usage on Tazarotene's label. DailyMed label · 1cf1faef-73b8-4ab2-a4c8-521f0bd3fc10 · 2026-05-18

24 registered trials of Tazarotene — at which phases?

Registered studies posting no result
12 of 24

24 registered studies of Tazarotene: 10 phase2, 6 phase1, 4 phase3, 3 phase4, 2 na. CLINICALTRIALS_SNAPSHOT · 2026-09-01

140 with a PubMed record

Show the evidence
  • phase2
    10
  • phase1
    6
  • phase3
    4
  • phase4
    3
  • na
    2
  • completed
    21
2 more recorded rows
  • unknown
    2
  • terminated
    1

recorded 2026-09-01 · last checked 2026-09-04

Why did Tazarotene's trial NCT04071756 stop?

1 recorded trial of Tazarotene stopped. CLINICALTRIALS_SNAPSHOT · 2026-09-01

"Difficulty with patient recruitment"; 1 of 24 registered studies

Show the evidence
  • Trial NCT04071756
    terminated; "Difficulty with patient recruitment"

recorded 2026-09-01 · last checked 2026-09-04

Human studies of Tazarotene used Aczone Gel 5%; Tazorac Cream 0.1% — over how long?

studies of Tazarotene used the recorded amount. ClinicalTrials.gov · 2026-09-01

11 recorded entries; human; also "Aczone Gel 5%; Tazorac Cream 0.1%", "Tazorac Cream 0.1%", "Tazarotene Cream, 0.05%"

Show the evidence

human

  • NCT00834210
    Aczone Gel 5%; Tazorac Cream 0.1%
  • NCT00834210
    Tazorac Cream 0.1%
  • NCT02160665
    Tazarotene Cream, 0.05%
  • NCT02160665
    Reference: Tazorac Cream, 0.05%
  • NCT02411955
    Tazarotene Cream 0.1%
  • NCT02525822
    Tazorac Cream, 0.1%,
5 more recorded rows
  • human NCT02886702
    Tazarotene Cream 0.05%
  • human NCT02886702
    TAZORAC® (tazarotene) Cream 0.05%
  • human NCT03599193
    Tazarotene Lotion, 0.1%
  • human NCT03599193
    Tazarotene Cream, 0.1%
  • human NCT05704114
    Tazarotene 0.045% Lotion

recorded 2026-09-01 · last checked 2026-09-04

Tazarotene's half-life is 18 hours — which schedules were studied?

18 hours, the half-life Tazarotene's label states: "The half-life of tazarotenic acid was approximately 18 hours, following topical application of tazarotene to normal, acne or psoriatic skin." DailyMed label · 1cf1faef-73b8-4ab2-a4c8-521f0bd3fc10 · 2026-05-18

Show the evidence
  • half life pharmacokinetics
    18 hours; The half-life of tazarotenic acid was approximately 18 hours, following topical application of tazarotene to normal, acne or psoriatic skin.
  • metabolism pharmacokinetics
    Tazarotene and tazarotenic acid were metabolized to sulfoxides, sulfones and other polar metabolites which were eliminated through urinary and fecal pathways.

recorded 2026-05-18 · last checked 2026-09-04

Which 9 trials of Tazarotene posted no result?

Posted no result
9 of 9 completed trials
Registrations
NCT00648986, NCT00440024, NCT01019603, NCT01119651, NCT02411955 and NCT02160665, and 3 more
Completion dates
oldest 2006-12; newest 2022-05-01
Show the evidence

Trial

  • NCT00648986
    2006-12
  • NCT00440024
    2009-11
  • NCT01019603
    2009-12-20
  • NCT01119651
    2010-06-26
  • NCT02411955
    2015-02
  • NCT02160665
    2016-05
3 further recorded trials
  • NCT02849873
    2017-01
  • NCT03058744
    2017-01
  • NCT05704114
    2022-05-01

At the median, Tazarotene's trials enrolled 58.5 people — anything larger?

Median enrolment
58.5
Largest enrolment
1110
Registered trials counted
24

What do 108 spontaneous reports say about Tazarotene — and not say?

These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.

Tazarotene appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 108 reaction mentions were counted: skin exfoliation 15; erythema 15; application site pain 14; application site erythema 13. FAERS via Open Targets · CHEMBL1657 · 2026-06-24

Show the evidence
  • skin exfoliation
    15
  • erythema
    15
  • application site pain
    14
  • application site erythema
    13
  • application site discolouration
    10
  • skin depigmentation
    10
4 more recorded rows
  • pregnancy
    9
  • skin burning sensation
    8
  • burning sensation
    8
  • skin irritation
    6

recorded 2026-06-24 · last checked 2026-09-04

Which 10 reactions does Tazarotene's label not list?

application site discolouration, application site erythema and application site pain and 7 more reported for Tazarotene, absent from its label. FAERS via Open Targets · CHEMBL1657 · 2026-06-24

2 label terms; 10 reported and unlisted; 1cf1faef-73b8-4ab2-a4c8-521f0bd3fc10

Show the evidence
  • application site discolouration
    count not stated
  • application site erythema
    count not stated
  • application site pain
    count not stated
  • burning sensation
    count not stated
  • erythema
    count not stated
  • pregnancy
    count not stated
4 more recorded rows
  • skin burning sensation
    count not stated
  • skin depigmentation
    count not stated
  • skin exfoliation
    count not stated
  • skin irritation
    count not stated

recorded 2026-06-24 · last checked 2026-09-04

Where it is registered
Identifiers, relations and other names

The exact record

ChEMBL id
CHEMBL1657
PubChem CID
5381
CAS number
118292-40-3
RxCUI
83947
InChIKey
OGQICQVSFDPSEI-UHFFFAOYSA-N
Trade name
Avage, Arazlo, Fabior, Tazarotene component of duobrii, Tazarotene component of idp-118, Tazorac, Zorac, Trilitas, Tazorac / Arazlo / Fabior / Avage / Trilitas, DUOBRII COMPONENT TAZAROTENE
Development code
AGN 190168, AGN190168
Also called
Idp-123, Tazaroteno, 3-PYRIDINECARBOXYLIC ACID, 6-((3,4-DIHYDRO-4,4-DIMETHYL-2H-1-BENZOTHIOPYRAN-6-YL)ETHYNYL)-, ETHYL ESTER, IDP-118 COMPONENT TAZAROTENE, TAZAROTENE [JAN], TAZAROTENE [MART.], TAZAROTENE [MI]
Salt form
tazorac cream
Sources (6)

Sources

ChEMBL 37 — CC BY-SA 3.0 Unported · ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Open Targets 26.06 — CC0 · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work

How these records are assembled · Which registers were checked

Index-quality checks
  • identity passed: no open identity hold
  • required summary fields resolved: 4 required field(s) not terminal: Why people use it, Best-supported result, Biggest unanswered question, Human evidence
  • public claims reviewed: 0 reviewed claim(s); drafts are never rendered
  • source coverage passed: 6 source rows
  • no critical contamination: no quarantine open
  • canonical metadata passed: slug and display name present
  • no raw internal fields: enforced by the copy-contract test over the rendered page

This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.